89724-32-3

Upstream product

• 61151-95-9 2-cyclohexanecarbonylamino-3-oxo-butyric acid ethyl ester 
• 107367-85-1 (S)-3-(Cyclohexanecarbonyl-amino)-4-oxo-pentanoic acid methyl ester 
• 89744-48-9 (S)-2-(Cyclohexanecarbonyl-amino)-succinic acid 4-methyl ester 
• 61152-00-9 2-cyclohexyl-5-methyl-oxazole-4-carboxylic acid ethyl ester 
• 61152-04-3 2-cyclohexyl-5-methyl-oxazole-4-carboxylic acid 
• 51655-86-8 2-cyclohexyl-5-methyl-oxazole-4-carbonyl chloride 
• 136058-64-5 4-chloromethyl-2-cyclohexyl-5-methyl-oxazole 
• 89724-31-2 2-Cyclohexyl-4-hydroxymethyl-5-methyloxazole 
• 401791-01-3 3-(cyclohexanecarbonyl-amino)-4-oxo-pentanoic acid benzyl ester 
• 2719-27-9 cyclohexanylcarbonyl chloride 
• 401791-02-4 (2-cyclohexyl-5-methyl-oxazol-4-yl)-acetic acid benzyl ester 
• 108192-92-3 (2-cyclohexyl-5-methyl-oxazol-4-yl)acetonitrile 

Downstream Products

• 132646-47-0 2-(2-cyclohexyl-5-methyl-oxazol-4-yl)-ethanol 

Relevant academic research and scientific papers

Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS

The present invention relates to compounds of formula (I) wherein R1 to R8 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

Application of the Dakin-West reaction for the synthesis of oxazole-containing dual PPARα/γ agonists

An improved method for the preparation of a series of oxazole-containing dual PPARα/γ agonists is described. A synthetic sequence utilizing a Dakin-West reaction was devised that allows for the introduction of the oxazole ring either late in the synthetic sequence via aminomalonate-derived chemistry or in pivotal SAR intermediates derived from aspartic acid.

Oxazolidinedione hypoglycemic agents

Compounds of the formulae STR1 where R is cycloalkyl or aryl; R1 is alkyl, X is O or C=O; A is O or S; and B is N or CH are useful as hypoglycemic agents.

Oxazolidinedione hypoglycemic agents

Compounds of the formulae where R is cycloalkyl or aryl; R1 is alkyl, X is O or C=O; A is O or S; and B is N or CH are useful as hypoglycemic agents.

Oxazoleacetic acid derivatives

A compound of the formula: STR1 wherein R1 is (A) a group of the formula, STR2 wherein R4 is H, a halogen or trifluoromethyl group, or (B) a group of the formula, STR3 wherein n is 0 or an integer of 1 to 3; R5 is H or an